ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

The March To Deliver Message Of Funding For Cancer Research, Access To Care

September 4, 1998

HHS Carcinogen Guidelines Draft

June 13, 1980

Clearinghouse Funds Two Carcinogens And A Threat To Humans

March 17, 1978

Fred Conrad, MDA VP, Shot To Death In Hospital Office

January 7, 1983

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

New Therapies For Genitourinary Cancers In Clinical Testing Presented At ASCO

July 25, 2003